Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1 in primary breast cancer
Authors:
- Volker R. JacobsVJVolker R. Jacobs
- Doris AugustinDADoris Augustin
- Arthur WischnikAWArthur Wischnik
- Marion KiechleMKMarion Kiechle
- Cornelia HössCHCornelia Höss
- Oliver SteinkohlOSOliver Steinkohl
- Brigitte RackBRBrigitte Rack
- Thomas KapitzaTKThomas Kapitza
- Peter KrasePKPeter Krase
- 1 August 2013
- journal article
- research article
- Published by Elsevier in The Breast
- Vol. 22 (4) , 436-443
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1Expert Review of Molecular Diagnostics, 2011
- Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × DocetaxelBMC Cancer, 2011
- Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1Expert Review of Molecular Diagnostics, 2010
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- Invasion Factors uPA/PAI-1 and HER2 Status Provide Independent and Complementary Information on Patient Outcome in Node-Negative Breast CancerJournal of Clinical Oncology, 2003
- Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in CombinationJournal of Clinical Oncology, 2002
- Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer PatientsJNCI: Journal of the National Cancer Institute, 2002
- Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1JNCI: Journal of the National Cancer Institute, 2001
- Invasion marker PAI‐1 remains a strong prognostic factor after long‐term follow‐up both for primary breast cancer and following first relapseBreast Cancer Research and Treatment, 1999
- Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancerBreast Cancer Research and Treatment, 1993